Silicon Valley billionaires are obsessed with 'reprogramming' their bodies for longevity. The first human trial suggests they may be onto something.

Key Points:

• Silicon Valley billionaires like Jeff Bezos, Peter Thiel, Yuri Milner, and Sam Altman are investing heavily in cellular reprogramming, a longevity science technique aimed at reversing age-related decline by rejuvenating cells.
• Life Biosciences is conducting the first human trial of cellular reprogramming, targeting glaucoma with a novel eye injection therapy; early safety data shows no major side effects and some patients experienced significant vision improvements.
• Experts caution that results are preliminary and more data is needed to confirm true regeneration, but an independent board has approved a higher dose for upcoming trial participants to possibly enhance effectiveness.
• If successful, this approach could be expanded to treat various age-related diseases such as arthritis, high blood pressure, fatty liver disease, and Alzheimer's, potentially serving as a "master key" for multiple conditions.
• Other biotech startups backed by tech billionaires, including Altos Labs, New Limit, and Retro Biosciences, are also preparing for human trials in cellular reprogramming, signaling a competitive race to develop longevity therapies.